<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503659</url>
  </required_header>
  <id_info>
    <org_study_id>335/06/FFM</org_study_id>
    <nct_id>NCT00503659</nct_id>
  </id_info>
  <brief_title>Comparison of Two Methods of Bronchial Methacholine Provocation</brief_title>
  <official_title>Comparison of Two Methods of Bronchial Methacholine Provocation: PC 20 FEV1 Versus PD 20 FEV1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is meant to compare two routine diagnostic approaches in patients with bronchial
      asthma. Patients are challenged with methacholine in order to measure their bronchial
      response. We compare the evaluation of the effects of incremental concentrations versus
      incremental dosages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchial methacholine challenge is well established in asthma diagnostic and research
      purposes. ATS guidelines provide a short five-breath dosimeter protocol using a five-step
      dilution schedule. The Viasys APS system enables a feasible and less time consuming
      provocation with incremental dosages. In 48 young adults with bronchial hyperreactivity (BHR)
      the ATS-protocol with a five-step protocol using a single dilution of 16 mg/ml methacholine
      should be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>correlation of the two parameters PC20 FEV1 and PD20 FEV1</measure>
    <time_frame>feb 2007 - dec 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>kappa index of concordance: reliability of the two procedures as to a FEV1 decrease of 20% depending on methacholine concentration</measure>
    <time_frame>see above</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Bronchial Hyperreactivity</condition>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine challenge, five-breath dosimeter protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methacholine challenge five incremental dosages protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial methacholine provocation</intervention_name>
    <description>A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>DeVilbiss nebulizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bronchial methacholine provocation</intervention_name>
    <description>A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Viasys APS nebulizer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age 12-45 years

          -  Known bronchial hyperreactivity

        Exclusion Criteria:

          -  Age &lt; 12 &gt; 45 years

          -  Clinical asthma requiring regular inhalation

          -  Vital capacity &lt; 80%

          -  FEV1 &lt; 75%

          -  Chronic disease conditions or infections

          -  Pregnancy

          -  Inhalative or systemic steroid use

          -  Substance abuse

          -  Incapability of understanding the study's purpose and performance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University, Department of Pulmonology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goethe University, Department of Pulmonology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29.</citation>
    <PMID>10619836</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Johannes Schulze MD</investigator_full_name>
    <investigator_title>Consultant Pediatric Allergy and Pulmonol√≥gy</investigator_title>
  </responsible_party>
  <keyword>PC20 FEV1</keyword>
  <keyword>PD20FEV1</keyword>
  <keyword>bronchial hyperreactivity</keyword>
  <keyword>bronchial asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

